Ashvattha Therapeutics Secures $50 Million in Series B Funding Extension
Ashvattha Therapeutics, a clinical-stage company focused on developing nanomedicine therapeutics, has secured additional financing of up to $50 million. This funding extension is part of its Series B and is led by Tribe Capital, with existing investors led by Natural Capital also participating.
The company is advancing a new class of therapeutics that can traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation. This approach is built on over twenty years of research at Johns Hopkins University and has been validated through four safety studies and three Phase 2a trials.
The funding will be used to complete the ongoing Phase 2 ophthalmology trial and Phase 1/2 neuroinflammation trial. Ashvattha’s at-home monthly subcutaneously-administered hydroxyl dendrimer therapeutic (HDT) for neovascular (wet) age-related macular degeneration (wet AMD) and diabetic macula edema (DME) has demonstrated a substantial reduction in treatment burden.
The interim Phase 2 trial results will be presented by the Principal Investigator, Dr. Michael Singer, at the Angiogenesis 2025 meeting. This presentation will highlight the potential of Ashvattha’s HDT platform to address various diseases, including inflammation, cancer, heart disease, aging disorders, autoimmune, and neurological diseases.
Ashvattha’s proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs). These HDTs link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. This precision medicine approach has the potential to change the standard of care across neurology, ophthalmology, hyperinflammatory diseases, and neuro-oncology.
The company believes that its platform of over one hundred HDTs has reached a critical point where its impact on the human population can be seen in the next few years. With this additional funding, Ashvattha is well-positioned to advance its clinical trials and bring its innovative therapeutics to market.
The investment by Tribe Capital and existing investors underscores the confidence in Ashvattha’s technology and its potential to address a wide range of diseases. The company’s focus on precision medicine and its ability to selectively target and reprogram activated cells in regions of inflammation make it a promising player in the biotechnology industry.
Ashvattha Therapeutics is headquartered in Redwood City, California, and was founded in 2015. The company has a strong leadership team and has expanded its team with key appointments, including Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors.
The company’s progress in developing its HDT platform and advancing its clinical trials positions it for significant growth and impact in the healthcare industry. With this additional funding, Ashvattha is poised to make significant strides in bringing its innovative therapeutics to patients in need.
See more funded startups in USA.